A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, first-in-human (FIH) Phase I study to evaluate the safety,
tolerability, and preliminary efficacy of a humanized anti-CD47 monoclonal antibody
(HMPL-A83) in patients with advanced malignant neoplasm.